Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae
Received 14 December 2018
Accepted for publication 27 March 2019
Published 29 May 2019 Volume 2019:14 Pages 3983—3993
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Anderson Oliveira Lobo
Umar Farooq,1,* Touqeer Ahmad,1,* Ajmal Khan,2 Rizwana Sarwar,1 Jazib Shafiq,3 Yasir Raza,4 Ayaz Ahmed,3 Safi Ullah,5 Najeeb Ur Rehman,2 Ahmed Al-Harrasi2
1Department of Chemistry, COMSATS University Islamabad Abbottabad Campus, Abbottabad, Pakistan; 2Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Sultanate of Oman; 3Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan; 4Department of Microbiology, University of Karachi, Karachi, Pakistan; 5Department of Pharmacy, University of Peshawar, Peshawar, Pakistan
*These authors contributed equally to this work
Background: Infections caused by drug resistant bacteria are a major health concern worldwide and have prompted scientists to carry out efforts to overcome this challenge. Researchers and pharmaceutical companies are trying to develop new kinds of antimicrobial agents by using different physical and chemical methods to overcome these problems.
Materials and methods: In the present study, rifampicin conjugated silver (Rif-Ag) nanoparticles have successfully been synthesized using a chemical method. Characterization of the nanoparticles was performed using a UV-Vis spectrophotometer, FTIR, SEM, TEM, and AFM.
Results: The AFM, SEM, and TEM results showed that the average particle size of Rif-Ag nanoparticles was about 15–18±4 nm. The FTIR spectra revealed the conjugation of –NH2 and –OH functional moiety with silver nanoparticles surface. Considering the penetrating power of rifampicin, the free drug is compared with synthesized nanoparticle for antimicrobial, biofilm inhibition, and eradication potential. Synthesized nanoparticles were found to be significantly active as compared to drug alone.
Conclusion: This study has shown greater biofilm inhibitory and eradicating potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae, as evident by crystal violet, MTT staining, and microscopic analysis. So, it will be further modified, and studies for the mechanism of action are needed.
Keywords: rifampicin, silver nanoparticles, TEM, AFM, antibiofilm, Staphylococcus aureus, Klebsiella pneumoniae
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]